KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives $26.43 Average Price Target from Brokerages

by · The Cerbat Gem

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Get Free Report) has been given an average rating of “Moderate Buy” by the ten analysts that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, eight have given a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $26.4286.

A number of research firms have recently issued reports on KALV. Needham & Company LLC restated a “buy” rating and set a $28.00 price target on shares of KalVista Pharmaceuticals in a report on Friday, September 12th. HC Wainwright boosted their price target on shares of KalVista Pharmaceuticals from $20.00 to $27.00 and gave the company a “buy” rating in a report on Tuesday, July 8th. JMP Securities upped their target price on KalVista Pharmaceuticals from $27.00 to $28.00 and gave the company a “market outperform” rating in a report on Friday, September 12th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a research report on Wednesday, October 8th.

Read Our Latest Stock Analysis on KALV

Insider Buying and Selling

In other news, insider Paul K. Audhya sold 2,336 shares of the stock in a transaction that occurred on Monday, August 25th. The shares were sold at an average price of $13.42, for a total value of $31,349.12. Following the completion of the sale, the insider directly owned 122,505 shares of the company’s stock, valued at $1,644,017.10. This represents a 1.87% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Benjamin L. Palleiko sold 7,294 shares of the stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $15.84, for a total transaction of $115,536.96. Following the completion of the sale, the chief executive officer directly owned 395,189 shares of the company’s stock, valued at $6,259,793.76. This trade represents a 1.81% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 26,856 shares of company stock valued at $374,910 over the last three months. 4.30% of the stock is owned by insiders.

Institutional Investors Weigh In On KalVista Pharmaceuticals

Institutional investors have recently made changes to their positions in the company. Earned Wealth Advisors LLC acquired a new stake in shares of KalVista Pharmaceuticals during the 1st quarter valued at about $44,000. BNP Paribas Financial Markets lifted its holdings in KalVista Pharmaceuticals by 47.0% in the 2nd quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company’s stock worth $46,000 after purchasing an additional 1,292 shares during the last quarter. CWM LLC lifted its holdings in KalVista Pharmaceuticals by 12,636.1% in the 1st quarter. CWM LLC now owns 4,585 shares of the specialty pharmaceutical company’s stock worth $53,000 after purchasing an additional 4,549 shares during the last quarter. Wolverine Asset Management LLC acquired a new stake in KalVista Pharmaceuticals in the 3rd quarter worth approximately $57,000. Finally, KLP Kapitalforvaltning AS acquired a new stake in KalVista Pharmaceuticals in the 3rd quarter worth approximately $63,000.

KalVista Pharmaceuticals Price Performance

KALV stock opened at $10.76 on Friday. KalVista Pharmaceuticals has a 52-week low of $7.30 and a 52-week high of $17.28. The company’s 50 day simple moving average is $12.54 and its 200-day simple moving average is $12.87. The firm has a market capitalization of $543.63 million, a P/E ratio of -2.73 and a beta of -0.15.

KalVista Pharmaceuticals (NASDAQ:KALV – Get Free Report) last released its quarterly earnings results on Thursday, September 11th. The specialty pharmaceutical company reported ($1.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.91) by ($0.21). The firm had revenue of $1.43 million for the quarter, compared to analyst estimates of $1.97 million. Sell-side analysts predict that KalVista Pharmaceuticals will post -3.56 EPS for the current fiscal year.

KalVista Pharmaceuticals Company Profile

(Get Free Report)

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).

Featured Stories